Is Hashimoto thyroiditis associated with hyperparathyroidism?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Is Hashimoto Thyroiditis Related to Hyperparathyroid Disease?

Yes, there is a documented association between Hashimoto thyroiditis and primary hyperparathyroidism (PHPT), though the relationship appears to be one of co-occurrence rather than direct causation, with prevalence rates suggesting these conditions occur together more frequently than would be expected by chance alone.

Evidence for the Association

The literature demonstrates a clear pattern of co-existence between these two autoimmune/endocrine conditions:

Prevalence Data:

  • In a large prospective study of 45,231 patients, among 2,267 patients with confirmed Hashimoto thyroiditis (elevated anti-TPO antibodies), 1.89% had concurrent PHPT 1. This is substantially higher than the general population prevalence of PHPT (approximately 0.3%).
  • The frequency of Hashimoto thyroiditis among PHPT patients has been reported at 37.6%, which does not differ significantly from the general population rate of 32.5% 2.

Clinical Case Evidence:

  • Multiple case reports and series document this association, including unusual presentations such as parathyroid adenomas and hyperplasia occurring alongside Hashimoto thyroiditis 3.
  • A historical series identified 17 women who developed PHPT after treatment for hypothyroidism secondary to Hashimoto thyroiditis, with hyperparathyroidism manifesting 2 months to 30 years after initiating thyroxine therapy 4.

Proposed Mechanisms

Several hypotheses have been suggested for this association:

  • Autoimmune linkage: Both conditions may share common genetic predisposition or autoimmune inflammatory processes 1
  • TSH stimulation: Elevated TSH levels from untreated hypothyroidism might trigger parathyroid hyperfunction, supported by experimental data 5
  • Unmasking effect: Treatment of hypothyroidism with thyroxine may unmask previously subclinical hyperparathyroidism 4
  • Anatomic proximity: The close embryologic and anatomic relationship between thyroid and parathyroid glands in conditions like thyroid hemiagenesis 3

Clinical Implications

For patients with Hashimoto thyroiditis:

  • Maintain awareness that PHPT occurs at approximately 6-fold higher frequency (1.89% vs 0.3%)
  • Measure serum calcium if symptoms suggestive of hypercalcemia develop (kidney stones, bone pain, osteoporosis, polyuria)
  • Consider baseline and periodic calcium monitoring, particularly before initiating and during thyroxine therapy 4

For patients with PHPT:

  • Screen for thyroid autoimmunity with anti-TPO antibodies, especially in women
  • The presence of concurrent Hashimoto thyroiditis does not alter bone metabolism markers or change the management approach for PHPT 2
  • Standard PHPT treatment guidelines apply regardless of thyroid disease status 6, 7, 8

Important Caveats

  • The association does not imply causation: Current evidence suggests co-occurrence rather than one condition directly causing the other
  • Bone metabolism is not affected: Co-existing Hashimoto thyroiditis does not appear to have additional effects on bone markers or calcium-phosphate metabolism in PHPT patients 2
  • Treatment priorities remain standard: The presence of Hashimoto thyroiditis does not change surgical indications or management strategies for PHPT 8
  • Vitamin D status matters: Before diagnosing PHPT in patients with Hashimoto thyroiditis, ensure vitamin D sufficiency for at least 6 months, as vitamin D deficiency can cause secondary hyperparathyroidism that mimics PHPT 6

Practical Approach

When encountering either condition:

  1. In Hashimoto patients: Check serum calcium and PTH if any symptoms of hypercalcemia emerge, or consider baseline screening given the 6-fold increased risk
  2. In PHPT patients: Measure anti-TPO antibodies to identify concurrent autoimmune thyroid disease
  3. Before treating hypothyroidism: Evaluate parathyroid function (calcium, PTH) to avoid unmasking subclinical hyperparathyroidism 4
  4. During follow-up: Monitor both conditions independently according to their respective guidelines

The relationship is clinically relevant primarily for surveillance purposes rather than altering treatment strategies for either condition.

References

3
Guideline

thyroid hemiagenesis: incidence, clinical significance, and genetic background.

The Journal of clinical endocrinology and metabolism, 2017

6
Guideline

chapter 2: primary hyperparathyroidism: diagnosis.

Annales d'endocrinologie, 2025

Related Questions

Are there antibodies that target the parathyroid glands in primary hyperparathyroidism similar to the autoantibodies seen in Hashimoto thyroiditis?
Which specialist should manage a patient with asymptomatic primary hyperparathyroidism?
What should be monitored in patients with hyperparathyroidism?
What dietary recommendations are appropriate for a patient with primary hyperparathyroidism?
In a patient with a 7-year history of progressive lower‑leg motor weakness and neuropathy due to primary hyperparathyroidism, can normalization of parathyroid function (e.g., via parathyroidectomy) lead to functional recovery?
What is the recommended infusion duration for a 2‑gram dose of cefepime administered intravenously?
When should the response to hair loss therapies such as topical minoxidil, oral finasteride, low‑dose oral minoxidil, low‑level laser therapy, and platelet‑rich plasma be assessed?
Will a 9‑day steroid‑free interval after a short 20 mg corticosteroid course of 4–5 days still suppress inflammatory changes and affect MRI visualization of lumbar region tumors?
Should Tobramycin 3 mg/mL (0.3%) ophthalmic solution be dosed every 8 hours or every 12 hours for bacterial conjunctivitis?
What are anti‑thyroid peroxidase (anti‑TPO) antibodies?
Does a brief pain relief from a short course of corticosteroids (20 mg daily for 4–5 days) followed by rapid recurrence of pain increase concern for malignancy as the cause of the symptoms?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.